FDA Releases CMC Postapproval Manufacturing Changes For Spec

This new FDA/CDER guidance represents the FDA's thinking regarding the types of changes to an approved biologics license application (BLA) that...

Related Keywords

Mark Durivage , Office Of Communication , International Council For Harmonisation , Office Of Pharmaceutical Quality , Quality Systems Compliance , Drug Evaluation , Biologics Evaluation , Manufacturing Changes , Specified Biological Products To Be Documented , Annual Reports , International Council , Manufacturing Practice Guidance , Active Pharmaceutical Ingredients , Risk Management , Quality System , Federal Food , Cosmetic Act , Approval Supplement Expedited Review Requested , Changes That , Considers Having , Approved Application , Specified Biotechnology , Specified Synthetic Biological Products , Pharmaceutical Quality ,